Recombinant Anti-IRF8 antibody [EPR20441] (ab207418)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR20441] to IRF8
- Suitable for: WB, IP, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-IRF8 antibody [EPR20441]
See all IRF8 primary antibodies -
Description
Rabbit monoclonal [EPR20441] to IRF8 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: THP-1 and Raji whole cell lysates; Human fetal spleen, tonsil and colon lysates. IHC-P: Human tonsil and non-hodgkin’s lymphoma tissues. IP: Raji whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR20441 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab207418 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Detects a band of approximately 48 kDa (predicted molecular weight: 48 kDa).
|
|
IP |
1/40.
|
|
IHC-P | (1) |
1/1000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000. Detects a band of approximately 48 kDa (predicted molecular weight: 48 kDa). |
IP
1/40. |
IHC-P
1/1000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Target
-
Function
Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Plays a negative regulatory role in cells of the immune system. -
Tissue specificity
Predominantly in lymphoid tissues. -
Sequence similarities
Belongs to the IRF family.
Contains 1 IRF tryptophan pentad repeat DNA-binding domain. -
Post-translational
modificationsUbiquitinated. Ubiquitination by TRIM21 in macrophages, a process that is strongly increased upon interferon gamma stimulation, leds to the enhanced transcriptional activity of target cytokine genes. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 3394 Human
- Omim: 601565 Human
- SwissProt: Q02556 Human
- Unigene: 137427 Human
-
Alternative names
- H ICSBP antibody
- H-ICSBP antibody
- HGNC:5358 antibody
see all
Images
-
Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling IRF8 with ab207418 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Nuclear staining on human tonsil (×200) [PMID: 18663414] [PMID: 16380510].
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded human non-hodgkin’s lymphoma tissue labeling IRF8 with ab207418 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ready to use. Nuclear staining on human non-hodgkin’s lymphoma.
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) ready to use.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
All lanes : Anti-IRF8 antibody [EPR20441] (ab207418) at 1/1000 dilution
Lane 1 : THP-1 (Human monocytic leukemia cell line) whole cell lysate
Lane 2 : Raji (Human Burkitt's lymphoma cell line) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 48 kDa
Observed band size: 48 kDa
Exposure time: 1 minuteBlocking/Dilution buffer: 5% NFDM/TBST.
-
All lanes : Anti-IRF8 antibody [EPR20441] (ab207418) at 1/1000 dilution
Lane 1 : Human fetal spleen lysate
Lane 2 : Human tonsil lysate
Lane 3 : Human colon lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
Predicted band size: 48 kDa
Observed band size: 48 kDaBlocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: Lane 1: 30 seconds; Lane 2: 2 seconds; Lane 3: 15 seconds.
-
IRF8 was immunoprecipitated from 0.35 mg of Raji (Human Burkitt's lymphoma cell line) whole cell lysate with ab207418 at 1/40 dilution. Western blot was performed from the immunoprecipitate using ab207418 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Lane 1: Raji whole cell lysate 10 μg (Input).
Lane 2: ab207418 IP in Raji whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab207418 in Raji whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 1 second.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (6)
ab207418 has been referenced in 6 publications.
- McQuaid DC et al. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. Am J Clin Pathol 158:173-176 (2022). PubMed: 35460405
- Pingul BY et al. Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia. iScience 25:105139 (2022). PubMed: 36193052
- Gatti G et al. High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. Breast Cancer Res 23:40 (2021). PubMed: 33766090
- Deng Z et al. Keratinocyte-Immune Cell Crosstalk in a STAT1-Mediated Pathway: Novel Insights Into Rosacea Pathogenesis. Front Immunol 12:674871 (2021). PubMed: 34290700
- Cao Z et al. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Mol Cell 81:3604-3622.e10 (2021). PubMed: 34358447
- Mohaghegh N et al. NextPBM: a platform to study cell-specific transcription factor binding and cooperativity. Nucleic Acids Res N/A:N/A (2019). PubMed: 30657937